// App-Quantinova.ai

: Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Researchers

Presenter

  • Paolo Strati

Principal Investigators

  • Tae Min Kim

  • Alexey V Danilov

  • Chan Y. Cheah

  • Dok Hyun Yoon

  • Wojciech Jurczak

  • Shringi Sharma

  • Jeong Lim Yoon

  • Serena Arduini

  • Jamal Saeh

  • Richard F. Olsson

  • Gareth Gregory

Medical Centers

  • Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

  • City of Hope Comprehensive Cancer Center, Duarte, CA

  • Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

  • Linear Clinical Research, Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia

  • The University of Texas MD Anderson Cancer Center, Houston, TX

  • Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Asan Medical Center, Seoul, Korea, Republic of (South)

Locations

  • Poland

  • Republic of South Korea

  • United States

  • Australia

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved